MX350666B - Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia. - Google Patents
Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia.Info
- Publication number
- MX350666B MX350666B MX2013010384A MX2013010384A MX350666B MX 350666 B MX350666 B MX 350666B MX 2013010384 A MX2013010384 A MX 2013010384A MX 2013010384 A MX2013010384 A MX 2013010384A MX 350666 B MX350666 B MX 350666B
- Authority
- MX
- Mexico
- Prior art keywords
- hyperuricemia
- compositions
- disorders associated
- metabolic disorders
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451600P | 2011-03-11 | 2011-03-11 | |
| PCT/US2012/027993 WO2012125359A1 (en) | 2011-03-11 | 2012-03-07 | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013010384A MX2013010384A (es) | 2013-10-07 |
| MX350666B true MX350666B (es) | 2017-09-12 |
Family
ID=46796094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010384A MX350666B (es) | 2011-03-11 | 2012-03-07 | Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8865689B2 (enExample) |
| EP (1) | EP2683372B1 (enExample) |
| JP (1) | JP6012639B2 (enExample) |
| KR (1) | KR101567885B1 (enExample) |
| CN (1) | CN103429236B (enExample) |
| AR (1) | AR085662A1 (enExample) |
| AU (1) | AU2012229443B2 (enExample) |
| BR (1) | BR112013022332A2 (enExample) |
| CA (1) | CA2829101C (enExample) |
| ES (1) | ES2634562T3 (enExample) |
| IL (1) | IL228030B (enExample) |
| MX (1) | MX350666B (enExample) |
| PT (1) | PT2683372T (enExample) |
| RU (1) | RU2603050C2 (enExample) |
| TW (1) | TWI505827B (enExample) |
| WO (1) | WO2012125359A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2560310T3 (es) * | 2010-04-08 | 2016-02-18 | Twi Biotechnology, Inc. | Métodos de uso de diacereína como una terapia concomitante para diabetes |
| AU2012229443B2 (en) | 2011-03-11 | 2017-03-02 | Twi Biotechnology, Inc. | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia |
| CN103638020A (zh) * | 2013-12-20 | 2014-03-19 | 中美华世通生物医药科技（武汉）有限公司 | 一种治疗痛风的新型药物组合物 |
| CN104491839B (zh) * | 2014-11-27 | 2016-06-22 | 青岛大学附属医院 | 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途 |
| KR101647348B1 (ko) * | 2014-12-30 | 2016-08-22 | 충남대학교산학협력단 | Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물 |
| MX2017013489A (es) * | 2015-04-20 | 2018-05-22 | Twi Biotechnology Inc | Formulaciones que contienen diacereina y metodos para la reduccion de los niveles en sangre de acido urico usando los mismos. |
| US20160303050A1 (en) * | 2015-04-20 | 2016-10-20 | Twi Biotechnology, Inc. | Formulations containing diacerein and methods of lowering blood levels of uric acid using the same |
| TWI684465B (zh) * | 2015-04-22 | 2020-02-11 | 安成生物科技股份有限公司 | 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法 |
| MX373702B (es) | 2015-07-01 | 2020-05-07 | Twi Biotechnology Inc | Formulaciones topicas de diacereina o rheina y sus usos. |
| MX2018002049A (es) * | 2015-08-17 | 2018-06-15 | Twi Biotechnology Inc | Diacereina o sus analogos para inhibir la expresion de proteina como mota relacionada a la apoptosis que contiene un dominio de reclutamiento de caspasa (asc), expresion de dominios de pirina y familia nlr que contienen 3 (nlrp3) y/o formacion de complejo de inflamasoma de nlrp3. |
| KR101863604B1 (ko) * | 2016-04-08 | 2018-06-04 | 한국 한의학 연구원 | 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물 |
| TW201739448A (zh) * | 2016-05-06 | 2017-11-16 | 安成生物科技股份有限公司 | 用於治療及/或預防血液相關疾病之方法及配方 |
| CN107468955B (zh) * | 2017-09-06 | 2020-07-24 | 大连医科大学 | 治疗痛风性关节炎的中药及制备方法 |
| KR102361526B1 (ko) * | 2019-07-02 | 2022-02-11 | 한국 한의학 연구원 | 난각막을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물 |
| CN113082012A (zh) * | 2021-04-26 | 2021-07-09 | 北京亿药科技有限公司 | 紫苏烯在制备预防和/或治疗高尿酸血症药物中的应用 |
| US12269875B2 (en) * | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04009698A (es) * | 2004-10-04 | 2006-04-05 | Maria Elena Garcia Armenta | Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam. |
| DK2124997T3 (da) * | 2006-10-20 | 2012-08-27 | Regeneron Pharma | Anvendelse af IL-1-antagonister til behandling af gigt og pseudogigt |
| US7632490B2 (en) * | 2006-10-20 | 2009-12-15 | Regeneron Pharmaceuticals, Inc. | Use of IL-1 antagonists to treat gout |
| EP2471517A3 (en) * | 2007-09-14 | 2012-12-26 | Wockhardt Limited | Rhein or diacerein compositions |
| US20100150938A1 (en) * | 2008-07-03 | 2010-06-17 | University Of Massachusetts | Methods and compositions for reducing inflammation and treating inflammatory disorders |
| TWI473610B (zh) * | 2008-10-28 | 2015-02-21 | Twi Biotechnology Inc | 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物 |
| AU2012229443B2 (en) | 2011-03-11 | 2017-03-02 | Twi Biotechnology, Inc. | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia |
-
2012
- 2012-03-07 AU AU2012229443A patent/AU2012229443B2/en not_active Ceased
- 2012-03-07 BR BR112013022332A patent/BR112013022332A2/pt not_active IP Right Cessation
- 2012-03-07 ES ES12757767.4T patent/ES2634562T3/es active Active
- 2012-03-07 KR KR1020137026784A patent/KR101567885B1/ko not_active Expired - Fee Related
- 2012-03-07 JP JP2013557816A patent/JP6012639B2/ja not_active Expired - Fee Related
- 2012-03-07 CA CA2829101A patent/CA2829101C/en not_active Expired - Fee Related
- 2012-03-07 PT PT127577674T patent/PT2683372T/pt unknown
- 2012-03-07 MX MX2013010384A patent/MX350666B/es active IP Right Grant
- 2012-03-07 EP EP12757767.4A patent/EP2683372B1/en not_active Not-in-force
- 2012-03-07 WO PCT/US2012/027993 patent/WO2012125359A1/en not_active Ceased
- 2012-03-07 CN CN201280012914.9A patent/CN103429236B/zh not_active Expired - Fee Related
- 2012-03-07 US US13/414,264 patent/US8865689B2/en not_active Expired - Fee Related
- 2012-03-07 RU RU2013145498/14A patent/RU2603050C2/ru not_active IP Right Cessation
- 2012-03-09 TW TW101108193A patent/TWI505827B/zh not_active IP Right Cessation
- 2012-03-12 AR ARP120100799A patent/AR085662A1/es unknown
-
2013
- 2013-08-19 IL IL228030A patent/IL228030B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2683372A4 (en) | 2014-08-06 |
| EP2683372A1 (en) | 2014-01-15 |
| WO2012125359A1 (en) | 2012-09-20 |
| ES2634562T3 (es) | 2017-09-28 |
| BR112013022332A2 (pt) | 2017-05-30 |
| KR20140019795A (ko) | 2014-02-17 |
| RU2603050C2 (ru) | 2016-11-20 |
| CN103429236A (zh) | 2013-12-04 |
| AU2012229443B2 (en) | 2017-03-02 |
| IL228030B (en) | 2018-01-31 |
| TW201249432A (en) | 2012-12-16 |
| PT2683372T (pt) | 2017-10-25 |
| KR101567885B1 (ko) | 2015-11-10 |
| RU2013145498A (ru) | 2015-04-20 |
| MX2013010384A (es) | 2013-10-07 |
| AR085662A1 (es) | 2013-10-16 |
| NZ614486A (en) | 2014-11-28 |
| CA2829101A1 (en) | 2012-09-20 |
| US20120232044A1 (en) | 2012-09-13 |
| CN103429236B (zh) | 2016-09-21 |
| IL228030A0 (en) | 2013-09-30 |
| US8865689B2 (en) | 2014-10-21 |
| CA2829101C (en) | 2019-08-20 |
| JP6012639B2 (ja) | 2016-10-25 |
| TWI505827B (zh) | 2015-11-01 |
| EP2683372B1 (en) | 2017-07-12 |
| JP2014507476A (ja) | 2014-03-27 |
| AU2012229443A1 (en) | 2013-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX350666B (es) | Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia. | |
| CY1123460T1 (el) | Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης | |
| AR090601A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos | |
| CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
| CL2013003638A1 (es) | Compuestos inhibidores de metaloenzimas; composición que comprende dichos compuestos; uso de la composición para tratar o prevenir una enfermedad asociada a metaloenzimas en plantas; uso para inhibir metaloenzimas en microorganismos y tratar un trastorno fúngico en plantas. | |
| CO6630082A2 (es) | Tratamiento de lupus nefritis usando laquinimod | |
| BR112012023021A2 (pt) | compostos de indazol e seus usos | |
| BR112016009889A2 (pt) | ?compostos agonistas duplos gip-glp-1 e métodos? | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| BR112015022197A2 (pt) | tratamento de cataplexia | |
| RU2018145985A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| AR084691A1 (es) | Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel | |
| CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| BR112014009418A2 (pt) | macrociclos peptidomiméticos | |
| CR20130377A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
| CO6630086A2 (es) | Tratamiento de artritis por lupus usando laquinimod | |
| BR112013029246A2 (pt) | 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico | |
| MX382516B (es) | Composiciones y metodos para absorcion transmucosa. | |
| GT201400069A (es) | Composiciones farmaceuticas | |
| ECSP13012658A (es) | Composiciones y métodos para el tratamiento de la mielofibrosis | |
| BR112012033738A2 (pt) | método para o tratamento de transtorno bipolar | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| MX347927B (es) | Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb. | |
| AR092103A1 (es) | Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |